<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406145</url>
  </required_header>
  <id_info>
    <org_study_id>0777-CL-0030</org_study_id>
    <nct_id>NCT01406145</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil</brief_title>
  <official_title>A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to determine the safety and tolerability of ASP0777 in subjects with
      Alzheimer's Disease (AD) taking a stable dose of donepezil.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of subjects with adverse events</measure>
    <time_frame>Up to 56 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic assessment of AUC, maximum concentration (Cmax), minimum concentration (Cmin) and time to maximum concentration (tmax) through analysis of blood samples</measure>
    <time_frame>Up to 56 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ASP0777 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 low dose for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP0777 low dose, then high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP0777 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0777 high dose for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP0777</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>ASP0777 low dose</arm_group_label>
    <arm_group_label>ASP0777 low dose, then high dose</arm_group_label>
    <arm_group_label>ASP0777 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a Mini-Mental Status Exam score of 18-26

          -  Subject has a diagnosis of &quot;probable&quot; Alzheimer's Disease

          -  Subject has used donepezil for at least 3 months and has been on a stable dose for at
             least 6 weeks prior to screening

          -  Subject has a reliable adult who is residing with him/her during the outpatient
             portion of the study

          -  Subject is medically stable

          -  Subject has adequate cognitive, hearing, vision, and language skills

          -  Subject is able to ingest oral tablets

        Exclusion Criteria:

          -  Subject has received any investigational product in another clinical study or
             post-marketing clinical study within past 3 months

          -  Subject has any clinically significant abnormal laboratory tests

          -  Subject is a female who is pregnant, lactating or of childbearing potential who
             refuses to use a form of contraception during the study

          -  Subject has a history of a drug allergy or intolerance to memantine or a related
             compound

          -  Subject is currently using anti-dementia drugs (except for donepezil) or has used any
             such drugs within the last 4 weeks

          -  Subject has a score of 2 on item 16 of Cornell Scale for Depression in Dementia (CSDD)
             or has an overall CSDD score &gt; 10

          -  Subject is using off-label medicines, non-medicinal compounds, or dietary aids/food
             supplements to improve cognition that have not been at a stable dose for at least 4
             weeks prior to Screening and/or are anticipated to change dosing regimen during the
             study

          -  Subject has a history of drug or alcohol abuse within the past 12 months or subject
             consumes &gt; 1 drink of alcohol daily, or is unable to refrain from alcohol during the
             study

          -  Subject is a current smoker or recently quit smoking (within the past 12 months)

          -  Subject has a clinically significant medical condition that is unstable or is likely
             to become unstable during the course of the study

          -  Subject has history of seizures, other than febrile seizures during infancy

          -  Subject has history of repeated falls within past 6 months

          -  Subject has a major psychiatric illness or has received treatment for symptoms of a
             major psychiatric illness within past 1 year. Mild psychiatric disorders are allowable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Research Network, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>ASP0777</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

